Aytu acquired potential first-ever approved treatment for vEDS. Learn more Neos merger expands Aytu therapeutic reach to ADHD market. Learn more Good health starts early. Aytu pediatric medicines. Learn more A family of innovative products that’s perfect for yours. Learn more Aytu acquires potential breakthrough treatment for rare, inherited pediatric-onset disorder. Learn more ADHD affects people of all ages and all stages of life. Learn more See the light. Healight study for COVID-19. Learn more Corporate Overview Stock Information Press Releases Events & Presentations SEC Filings Financial Statements Corporate Governance Leadership Investor FAQs Analyst Coverage IR Contacts Investor Alerts Form 8937 Press Releases
